Comparing of Alterity Therapeutics Limited (ATHE) and Its Peers

As Biotechnology company, Alterity Therapeutics Limited (NASDAQ:ATHE) is competing with its competitors based on the profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.

Insider and Institutional Ownership

Alterity Therapeutics Limited has 3.1% of its shares owned by institutional investors vs. an average of 53.20% institutional ownership for its rivals. 18.7% of Alterity Therapeutics Limited shares are owned by company insiders. Comparatively, 8.45% of all Biotechnology companies shares are owned by company insiders.

Profitability

Table 1 has Alterity Therapeutics Limited and its competitors’ net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Alterity Therapeutics Limited 809,925,093.63% -56.40% -49.90%
Industry Average 812.10% 105.95% 28.39%

Earnings & Valuation

In next table we are comparing Alterity Therapeutics Limited and its competitors’ valuation, top-line revenue and net income.

Net Income Gross Revenue Price/Earnings Ratio
Alterity Therapeutics Limited 8.65M 1 0.00
Industry Average 33.76M 4.16M 35.97

Analyst Ratings

Table 3 provides breakdown of recent ratings for Alterity Therapeutics Limited and its competitors.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Alterity Therapeutics Limited 0 0 0 0.00
Industry Average 1.10 1.78 2.38 2.81

As a group, Biotechnology companies have a potential upside of 168.19%.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of Alterity Therapeutics Limited and its rivals.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Alterity Therapeutics Limited -9.73% -21.09% -40.59% -28.87% -53.26% -21.09%
Industry Average 5.82% 9.20% 28.08% 41.63% 73.35% 54.83%

For the past year Alterity Therapeutics Limited had bearish trend while Alterity Therapeutics Limited’s rivals had bullish trend.

Liquidity

The Current Ratio and a Quick Ratio of Alterity Therapeutics Limited are 4.4 and 4.4. Competitively, Alterity Therapeutics Limited’s rivals have 7.07 and 6.86 for Current and Quick Ratio. Alterity Therapeutics Limited’s peers have better ability to pay short and long-term obligations than Alterity Therapeutics Limited.

Volatility & Risk

Alterity Therapeutics Limited is 3.00% more volatile than Standard and Poor’s 500 because the stock has a beta of 1.03. Competitively, Alterity Therapeutics Limited’s rivals are 76.75% more volatile than Standard and Poor’s 500, because of the 1.77 beta.

Dividends

Alterity Therapeutics Limited does not pay a dividend.

Summary

Alterity Therapeutics Limited’s peers beat Alterity Therapeutics Limited on 4 of the 4 factors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.